Alzheimer Disease Clinical Trial
Official title:
The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
The purpose of the study is to determine the long-term safety and exploratory efficacy of
NEUROSTEM®-AD, administered via an open brain surgery to subjects with dementia of the
Alzheimer's type, who were eligible for and enrolled in the earlier part of the phase I.
Aside from the subjects who completed the earlier part of the Phase I, 3 additional subjects
with comparable demographics and disease characteristics as the treatment group will be
enrolled into a control group, followed-up for 3 months, and compared for various disease
progression indicators with the treatment group.
The hypothesis is that NEUROSTEM®-AD is safe and effective in the treatment of dementia of
the Alzheimer's type.
Status | Recruiting |
Enrollment | 14 |
Est. completion date | September 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years to 75 Years |
Eligibility |
TEST GROUP Inclusion Criteria: - Subjects who have enrolled and completed the Phase I cliical trial: The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease - Subjects who are willing to participate in the study and sign the consent form Exclusion Criteria: - Females who are pregnant or nursing - Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study - Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening) - Subjects who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above CONTROL GROUP Inclusion Criteria: - Patients with a moderate alzheimer's disease, diagnosed with a dementia of alzheimer's type, according to the DSM-VI and NINCDS-ADRDA criteria, and shows amyloid-positive in a PIB-PET Exclusion Criteria: - Subjects with a psychological disease (i.e. depression, schizophrenia, bipolar disorder, etc) - Subjects with a dementia caused by other degenerative neurological diseases (infection of the CNS, such as HIV or Syphilis), head trauma, Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, and Parkinson's disease) - Subjects with a vascular dementia as determined by the clinical criteria of DSM IV and the imaging criteria of Erkinjuntii - Subjects with severe white matter hyperintensities (WMH); Severe WMH is defined as, according to Clinical Research Center for Dementia of South Korea, a condition in which the deep white matter is 25 mm or greater and the periventricular capping/banding is 10 mm or greater in lengths. - Subjects with a history of stroke within the 3 months prior to the study enrollment - Subjects with a severe liver disease (ALT/AST values are higher than twice the normal range) - Subjects with a severe renal disease (1.5mg/dL or more of serum creatinine) - Pregnant or lactating women - Subjects with abnormal findings of the clinical laboratory values at Visit 1: - Hemoglobin < 9.5g/dL in male < 9.0 g/dL in female - Total WBC count < 3000/mm3 - Total bilirubin = 3 mg/dL - Subjects with a suspected active lung disease, based on the chest X-ray result at Visit 1 - Females of childbearing age who does not practice medically acceptable method of contraception during the study - Subjects who have previously failed Screening for participation in this study - Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study - Subjects with a bleeding disorder (platelet count < 150,000/mm3; PT = 1.5; INR or aPTT = 1.5 X control - Subjects with a cancer (including brain tumor) - Subjects with a history of alcohol or drug abuse - Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening) - Patients who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Duk Lyul Na | Medipost Co Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | Incidence rate ot adverse events (vital signs, physical examination, mixed lymphocyte reaction, and laboratory tests) | upto 24 months post-op | Yes |
Secondary | Efficacy | Primary Efficacy Variable: ADAS-cog response rate, ADAS-cog response is defined as when ADAS-cog score at the end of the study is not worse than the Baseline score. Secondary Efficacy Variables: Changes in Seoul Instrumental Activities of Daily Living (S-IADL) Changes in Mini Mental State Examination Korean verson (K-MMSE) Changes in Caregiver-administered Neuropsuchiatric Inventory Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Changes in CMRglc: regional cerebral metabolic rate for glucose (FDG-PET) |
upto 24 months post-op | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |